Business

20/20 BioLabs licenses PSA velocity algorithm from University of South Carolina for cancer detection

Edited by Robert McTiernan··4 min read

20/20 BioLabs licenses a PSA velocity algorithm from the University of South Carolina, adding a longitudinal biomarker analysis tool to its multi-cancer early detection platform as the company pursues a broader diagnostics-as-a-service model.

20/20 BioLabs (Nasdaq: AIDX), based in Gaithersburg, Maryland, has entered an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm that tracks the rate of change in prostate-specific antigen levels over time. The technology, developed by James Hébert at USC's South Carolina Statewide Cancer Prevention and Control Program, is designed to identify rapidly growing prostate tumors before PSA levels cross standard clinical thresholds. 20/20 BioLabs plans to integrate the algorithm into its OneTest for Cancer platform and offer it to third-party clinical laboratories under software-as-a-service licenses. Financial terms were not disclosed.

Deal context

Conventional PSA screening relies on a single-point threshold — typically 4.0 ng/mL — to flag elevated risk, an approach that has been widely criticized for generating false positives from benign conditions such as prostatic hyperplasia and inflammation. The PSA Velocity Algorithm addresses this by analyzing serial PSA measurements over time and computing the rate of change, or velocity, of the biomarker. Aggressive prostate cancers tend to produce a sustained, accelerating PSA rise, whereas benign causes of PSA elevation generally do not show the same pattern of acceleration. By modeling the slope of PSA change across multiple time points, the algorithm is described by USC as capable of distinguishing men at higher risk for clinically significant disease from those with less aggressive presentations.

The approach is consistent with active surveillance frameworks now recommended by the National Comprehensive Cancer Network, which call for repeat PSA testing at regular intervals rather than single-point assessment. The algorithm's longitudinal design means it requires serial blood draws, positioning it naturally within monitoring protocols already in use at clinical sites.

Beyond prostate cancer, the two parties have indicated plans to conduct joint research developing analogous velocity algorithms for CA 125, a marker associated with ovarian cancer, and CA 19.9, associated with pancreatic cancer. Those programs remain at the discovery stage; no validated algorithms for either marker have been disclosed.

20/20 BioLabs operates a College of American Pathologists-accredited, CLIA-licensed laboratory in Gaithersburg and runs a shared CLIA infrastructure called CLIAx for overseas diagnostics companies seeking US market access. The company launched OneTest for Longevity, measuring inflammatory biomarkers, in February 2026. The PSA velocity license adds a prostate cancer risk stratification layer to the existing OneTest for Cancer product, which uses established protein biomarkers alongside clinical factors and AI-driven analytics.

The AllSci BriefSystematic R&D and deal news. Daily.

Industry and transaction context

University-to-industry licensing of diagnostic algorithms has become an increasingly active segment of academic technology transfer, driven in part by the US FDA's evolving framework for software as a medical device. The structure here — an exclusive worldwide license with a SaaS sublicensing pathway to third-party labs — is consistent with deals in which a small commercial laboratory seeks both to differentiate its own test menu and to generate a secondary revenue stream by licensing the underlying technology to competitors. That dual-channel model reduces dependence on a single commercialization pathway and lowers the risk that the asset's value is constrained by the licensee's own market reach.

The multi-cancer early detection space has attracted substantial capital and partnering activity in recent years. Illumina's (Nasdaq: ILMN) Grail unit, which developed the Galleri multi-cancer blood test, has been the most visible participant, though its regulatory and ownership trajectory has been complicated. Smaller players have pursued narrower, biomarker-specific strategies rather than attempting to build pan-cancer liquid biopsy platforms from scratch. 20/20 BioLabs' approach — assembling a multi-analyte platform by licensing discrete algorithmic tools from academic institutions — represents a capital-efficient alternative to internal assay development, though it introduces dependency on third-party IP and the validation timelines associated with each new algorithm.

The planned extension into CA 125 and CA 19.9 velocity algorithms is notable because both markers have well-documented specificity limitations in single-point measurements, making them candidates for the same longitudinal analytical approach applied to PSA. Whether the velocity methodology improves clinical utility for those markers would require prospective validation data, none of which has been disclosed.

No comparable financial benchmarks for algorithm licensing deals of this type were disclosed, and the absence of deal economics makes it difficult to assess how this transaction compares with recent university technology transfer agreements in the diagnostics sector.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article